Crinecerfont placebo for oral capsules
Sponsors
Neurocrine Biosciences Inc.
Conditions
Classic Congenital Adrenal Hyperplasia (CAH)
Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Active, not recruitingCTIS2023-509170-33-00
Start: 2021-11-23Target: 35Updated: 2026-01-14
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Active, not recruitingCTIS2023-509171-16-00
Start: 2020-11-23Target: 99Updated: 2025-11-19